IDH mutations have been found to result in neomorphic activity to metabolize α-ketoglutarate to R-2-hydroxyglutarate (2HG), an oncometabolite, which accumulates and inhibits chromatin-modifying enzymes and has been demonstrated to inhibit hBCATc expression in gliomas [28–31]. This evidence concerns the gene IDH1 and glioma.